Barbara Weber (TNGX) reports RSU grant, option award and tax share sales

Rhea-AI Filing Summary

Barbara Weber, Director and Executive Chair of Tango Therapeutics, Inc., reported multiple equity transactions. She acquired 37,522 shares of common stock on February 2, 2026 through restricted stock units that vest in full on February 1, 2027, subject to continued service.

On the same date she was granted a stock option for 222,132 shares at an exercise price of $11.94 per share, vesting in 12 equal monthly installments following January 1, 2026. To satisfy tax withholding under the issuer’s sell-to-cover policy, she automatically sold 30,186 shares at a weighted average price of $12.2573 and 333 shares at $12.8971 on February 3, 2026. After these transactions, she directly owned 1,629,254 shares of common stock and 222,132 options.

Insider Trade Summary

Net Buyer: 7,003 shares

Net Buy 4 txns

Insider Weber Barbara

Role Director, Executive Chair

Sold 30,519 shs ($374K)

Type	Security	Shares	Price	Value
Sale	Common Stock	30,186	$12.2573	$370K
Sale	Common Stock	333	$12.8971	$4K
Grant/Award	Stock Option (Right to Buy)	222,132	$0.00	$0.00
Grant/Award	Common Stock	37,522	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 222,132 shares (Direct); Common Stock — 1,629,254 shares (Direct)

Footnotes (5)

1. F1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date.
2. F2. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
3. F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
5. F5. This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

FAQ

What insider transactions did Barbara Weber report for Tango Therapeutics (TNGX)?

Barbara Weber reported receiving restricted stock units and a stock option grant, plus automatic share sales. She acquired 37,522 RSU-based shares, a 222,132-share option, and sold 30,186 and 333 shares to cover tax withholding obligations tied to RSU vesting.

How many Tango Therapeutics shares does Barbara Weber hold after this Form 4?

After the reported transactions, Barbara Weber directly holds 1,629,254 shares of Tango Therapeutics common stock. She also beneficially owns a stock option covering 222,132 additional shares, which vests in 12 equal monthly installments following January 1, 2026, subject to continued service.

Were Barbara Weber’s Tango Therapeutics share sales discretionary?

The sales were described as automatic and not at Barbara Weber’s discretion. Tango Therapeutics uses a sell-to-cover policy, so 30,186 and 333 shares were sold solely to satisfy tax withholding obligations arising from the vesting of restricted stock units granted to her.

What are the key terms of Barbara Weber’s new stock option in Tango Therapeutics?

Barbara Weber received a stock option to buy 222,132 Tango Therapeutics shares at an exercise price of $11.94. The option vests in 12 equal monthly installments following January 1, 2026, contingent on her continuous service with the company through each vesting date.

When do Barbara Weber’s restricted stock units in Tango Therapeutics vest?

Barbara Weber’s 37,522 restricted stock units vest in full on February 1, 2027. Each RSU converts into one share of Tango Therapeutics common stock, provided she remains in continuous service with the company through that stated vesting date.

At what prices were Barbara Weber’s Tango Therapeutics tax-related share sales executed?

The 30,186-share sale was executed at a weighted average price of $12.2573, across trades ranging from $11.88 to $12.875. The 333-share sale used a weighted average of $12.8971, within a narrower range from $12.88 to $12.91 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/04/2026 - 08:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weber Barbara

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MA 02215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Director, Executive Chair

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		37,522(1)	A	$0	1,659,773	D
Common Stock	02/03/2026		S(2)		30,186	D	$12.2573(3)	1,629,587	D
Common Stock	02/03/2026		S(2)		333	D	$12.8971(4)	1,629,254	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.94	02/02/2026		A		222,132		(5)	02/02/2036	Common Stock	222,132	$0	222,132	D

Explanation of Responses:

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date.

2. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Daniella Beckman, as attorney-in-fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.